Based on the fact that SB218078 is designed as a competitive binding inhibitor against chk1, we inferred that SB218078 could inhibit tumor angiogenesis by regulating the transcription of ZEB1 and thereby inhibiting the expression of VEGFR2. This evidence concerns the gene ZEB1 and neoplasm.